FDA Approval of Regeneron’s Hearing Loss Gene Therapy Breaks Barriers

FDA Approves Regeneron's Otarmeni, First Gene Therapy for Hearing Loss

Regeneron Pharmaceuticals has received FDA approval for Otarmeni, its gene therapy for congenital deafness caused by otoferlin protein deficiency. This marks the first gene therapy for hearing loss and the first treatment to target an underlying cause of the condition. Approved under the FDA’s Commissioner’s National Priority Voucher program, Otarmeni demonstrated clinically meaningful hearing improvements in 11 out of 12 participants in the pivotal Phase 1/2 CHORD study, with three patients achieving normal hearing. Regeneron will provide the therapy for free in the U.S., signifying a major milestone for the company and the field of gene therapy.

• Otarmeni's FDA approval is a landmark achievement, being the first gene therapy for hearing loss and the first to address an underlying genetic cause. This approval, facilitated by the Commissioner’s National Priority Voucher program, offers a transformative treatment for individuals with congenital deafness due to otoferlin deficiency, with Regeneron committing to provide it for free in the U.S.
• The approval is supported by robust data from the Phase 1/2 CHORD study, where 11 of 12 participants experienced clinically meaningful hearing improvements, and notably, three patients achieved normal hearing levels. Furthermore, Otarmeni distinguished itself by not causing any serious adverse events in the clinical trial, with only surgery-related adverse events reported, highlighting its favorable safety profile.
• Otarmeni represents a significant step forward for gene therapies delivered directly to organs, rather than systemically. The therapy involves a single, targeted injection of a viral-vectored gene therapy into the cochlea, demonstrating the potential for precise delivery to specific tissues and organs, a concept Regeneron aims to expand to other areas like muscle, CNS, and potentially the heart.

The Unmet Need in Congenital Otoferlin Deficiency Deafness

Congenital otoferlin deficiency deafness presents significant therapeutic challenges across multiple treatment modalities. While cochlear implantation remains the standard intervention, emerging gene therapy approaches face technical hurdles that limit their efficacy. Understanding these limitations is crucial for advancing treatment strategies for this monogenic form of deafness.

• Conventional hearing aids are ineffective for otoferlin deficiency due to the underlying pathophysiology of auditory neuropathy, where otoacoustic emissions remain present despite profound hearing loss

• Gene therapy vector capacity constraints pose a fundamental challenge, as the OTOF coding sequence (~6 kb) exceeds the preferred AAV vector cargo capacity (<5 kb), necessitating complex dual-vector approaches

• Incomplete cellular transduction with current AAV-mediated approaches achieves otoferlin expression in only approximately 30% of inner hair cells, resulting in partial rather than complete hearing restoration

• Physiological expression patterns remain difficult to achieve with gene therapy, as overexpression approaches struggle to recapitulate endogenous otoferlin levels and temporal expression profiles

• Limited efficacy in clinical trials demonstrates that while 75% of patients achieved the primary endpoint of ≤70 dB HL thresholds, only 25% (3 of 12) achieved normal hearing sensitivity with current gene therapy

• Age-dependent treatment windows may limit therapeutic success, though recent evidence suggests efficacy extends beyond early childhood to adolescents and young adults

• Technical delivery challenges persist in optimizing endoscopic and transmastoid injection procedures to minimize procedural risks while maximizing cochlear targeting efficiency

Otarmeni's CHORD Study: Restoring Hearing, Ensuring Safety

Recent clinical trials for congenital deafness caused by otoferlin protein deficiency demonstrate promising therapeutic breakthroughs. Five international groups are currently conducting human gene therapy trials using dual vector approaches to reconstitute full-length otoferlin protein. These studies represent the first successful applications of restorative gene therapy for hereditary hearing loss in humans.

• DB-OTO Clinical Trial (NCT05788536) - Open-label, single-group, first-in-human registrational study using dual adeno-associated virus 1 gene therapy delivering human OTOF complementary DNA via intracochlear infusion (7.2×10 vector genomes per ear) in 12 children with profound deafness

• Primary efficacy outcomes - 9 of 12 participants (75%) achieved average threshold on behavioral pure-tone audiometry of 70 dB HL or less at week 24, with 6 participants able to hear soft speech without assistive devices and 3 participants achieving normal hearing sensitivity

• Safety profile - Total of 67 adverse events occurred during or after treatment, with none leading to study discontinuation; comprehensive safety assessments included adverse events monitoring, laboratory results, and vestibular testing

• International trial network - Five groups conducting clinical trials across 51 centers in eight countries: Eye and ENT Hospital Fudan University (China), Lilly-Akouos (USA), Otovia (China), Regeneron (USA), and Sensorion (France), all reporting varying degrees of hearing improvement

• Therapeutic efficacy across age groups - Hearing improvements observed not only in young children but also in adolescents and young adults, with some cases achieving complete hearing restoration to normal levels

• Preclinical validation studies - AAV1-intein protein splicing system demonstrated superior performance over RNA splicing approaches, rescuing hearing in Otof mice to 35-70 dB with effects sustained for 12 months in both newborn and adult mice

Otarmeni's Approval: A Paradigm Shift in Auditory Medicine

The recent FDA approval of Regeneron's Otarmeni for congenital deafness due to otoferlin deficiency marks a profound moment in medical history, signaling a new era for the treatment of hereditary hearing loss. For decades, patients with severe to profound deafness have relied on prosthetic devices like cochlear implants, which, while life-changing, do not restore the native biological function of the cochlea. Otarmeni, as the first gene therapy for hearing loss, offers a fundamentally different approach: a targeted, potentially curative intervention that addresses the root genetic cause.

Clinical trials have consistently shown remarkable success with otoferlin gene therapy, with multiple research groups reporting significant hearing improvements, and some patients achieving normal hearing levels. Importantly, studies indicate that gene therapy patients exhibit more rapid improvements in auditory and speech performance, and even outperform cochlear implant recipients in challenging environments like speech in noise and music perception. This suggests a superior functional outcome that could redefine the standard of care for eligible patients.

However, this groundbreaking advance also brings important considerations. While initial safety data are encouraging, the long-term durability of gene expression and the potential for late-onset adverse effects remain areas requiring continued vigilance and data collection. Furthermore, not all forms of genetic deafness are solely peripheral; some are associated with central auditory dysfunctions that could temper the benefits of cochlear gene therapy, underscoring the need for precise patient selection. The technical challenges of precise inner ear delivery, though significantly advanced, also continue to be a focus for optimization. Regeneron's innovative decision to provide Otarmeni for free in the U.S. is a notable strategic move, potentially influencing future access models for ultra-rare disease therapies, but global affordability and equitable access will remain critical discussions as this technology expands. This approval is not just a win for Regeneron; it's a beacon of hope for millions affected by genetic hearing loss and a powerful validation for the entire field of gene therapy.